These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17071064)

  • 1. Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
    Taskinen MR
    Nutr Metab Cardiovasc Dis; 2006 Dec; 16(8):509-12. PubMed ID: 17071064
    [No Abstract]   [Full Text] [Related]  

  • 2. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
    Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
    [No Abstract]   [Full Text] [Related]  

  • 3. FIELD study.
    Rees A
    Diabet Med; 2006 Jul; 23 Suppl 3():6-12. PubMed ID: 16805876
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 5. Is it time to stop treating dyslipidaemia with fibrates?
    Benatar JR; Stewart RA
    N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(2):118-9. PubMed ID: 20532440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B
    Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
    Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
    Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
    Unnikrishnan R; Das R; Jaydip R; Sudhakaran C; Mohan V
    J Assoc Physicians India; 2009 Feb; 57():180-1. PubMed ID: 19582991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ
    Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus].
    Ruiz J; Egli M; Gianinazzi F; Izzo F; Voeffray Favre AC; Rossi I; Bodenman P
    Rev Med Suisse; 2010 Jun; 6(252):1176-8, 1180-1. PubMed ID: 20614751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy in the management of mixed dyslipidaemia.
    Cannon CP
    J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
    Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ;
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
    Forster T
    Orv Hetil; 2001 Jul; 142(29):1588-9. PubMed ID: 11494751
    [No Abstract]   [Full Text] [Related]  

  • 15. [Coronary heart disease prevention in type 2 diabetic patients. What is the value of fibrates?].
    MMW Fortschr Med; 2002 Oct; 144(42):65. PubMed ID: 12534006
    [No Abstract]   [Full Text] [Related]  

  • 16. Reducing ocular damage in type 2 diabetes: the FIELD study shows fenofibrate benefits.
    Cardiovasc J Afr; 2007; 18(6):400. PubMed ID: 18092120
    [No Abstract]   [Full Text] [Related]  

  • 17. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
    Magee G; Sharpe PC
    J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS
    Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [On behalf and the extent of evidence].
    Ruiz J
    Rev Med Suisse; 2010 Jun; 6(252):1171-2. PubMed ID: 20614750
    [No Abstract]   [Full Text] [Related]  

  • 20. [The FIELD study presented and published. Unconvincing results of fenofibrates in diabetic patients].
    Widimský J
    Vnitr Lek; 2006 Jan; 52(1):80-4. PubMed ID: 16526203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.